Eledon pharmaceuticals to present data from ongoing phase 1b trial of tegoprubart in patients undergoing kidney transplantation at the american society of nephrology kidney week 2023 annual meeting

Irvine, calif., oct. 13, 2023 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today announced that the company will present a poster at the american society of nephrology's upcoming kidney week 2023 annual meeting taking place in philadelphia, pa from november 2-5, 2023.
ELDN Ratings Summary
ELDN Quant Ranking